Cancer is rising at an increasingly alarming pace. Early-onset malignancies are climbing in younger adults, aggressive cancers are appearing in patients with little warning, and U.S. cancer mortality has departed sharply from its pre-pandemic trajectory. Against this backdrop, one of the most important questions in medicine is whether the unprecedented mass deployment of nucleoside-modified mRNA technology could be contributing to cancer initiation, reactivation, or accelerated progression.
We have now fully answered this question in a new paper titled “Potential Oncogenicity of Synthetic mRNA Vaccines: Convergent Mechanistic, Clinical, and Population Evidence for a Concurrent-Hit Model of Accelerated Malignancy” authored by John A. Catanzaro, NMD, PhD; Nicolas Hulscher, MPH (myself); Raphael B. Stricker, MD; Jamie K. Waselenko, MD, FACP, FICT; and Peter A. McCullough, MD, MPH.